{
    "nctId": "NCT03979339",
    "briefTitle": "Feasibility of a New Technology for Isolating Circulating Tumour Cells",
    "officialTitle": "Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor Cell",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 76,
    "primaryOutcomeMeasure": "Percentage of cases with identified circulating tumor cells.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old\n* Registered with a social security system\n* Signed, IRB-approved written informed consent\n* Belonging to one of the following group:\n* Group 1 - HER-2 positive breast cancer, defined as followed: histologically-proven, HER-2 positive breast cancer, with metastasis (stage IV) requiring first-line treatment\n* Group 2 - Advanced ovarian cancer, defined as followed: histologically-proven, stage III or IV ovarian cancer requiring first-line chemotherapy\n* Group 3 - Metastatic prostate cancer, defined as followed: histologically-proven, stage IV, castrate-resistant prostate cancer requiring chemotherapy with docetaxel or treatment with 2nd generation hormonal therapy (e.g. enzalutamide or abiraterone)\n* Groups 0 and 4 - Healthy volunteers defined as followed: No prior personal history of malignant disease\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Patient under guardianship or curatorship",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}